Get the Stockscreener App
0.2363
0.55%
0.0013
After Hours:
.24
0.0037
+1.57%
China Pharma Holdings Inc. stock is traded at $0.2363, with a volume of 996.52K.
It is up +0.55% in the last 24 hours and up +17.04% over the past month.
China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, cephalosporin oral solutions, and granules. The company's products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate and Ozagrel Sodium to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide to treat edema diseases; and Candesartan for hypertension. It also provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Anhydroandrographolide for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. In addition, the company offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Further, it provides Vitamin B6 injection; and Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors. The company offers its products through distributors, as well as through its network of 16 sales offices and approximately 1,000 sales representatives. China Pharma Holdings, Inc. is headquartered in Haikou, the People's Republic of China.
See More
Previous Close:
$0.235
Open:
$0.253
24h Volume:
996.52K
Relative Volume:
4.68
Market Cap:
$4.03M
Revenue:
$7.78M
Net Income/Loss:
$-3.11M
P/E Ratio:
-0.4923
EPS:
-0.48
Net Cash Flow:
$-72,500
1W Performance:
+10.78%
1M Performance:
+17.04%
6M Performance:
-36.32%
1Y Performance:
-68.07%
1-Day Range:
$0.2209
$0.2544
1-Week Range:
$0.2103
$0.2573
52-Week Range:
$0.17
$1.212
China Pharma Holdings Inc. Stock (CPHI) Company Profile
Name
China Pharma Holdings Inc.
Sector
Phone
86 898 6681 1730
Address
No. 17, Jinpan Road, Second Floor, Haikou
China Pharma Holdings Inc. Stock (CPHI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-10 | Initiated | Rodman & Renshaw | Mkt Outperform |
China Pharma Holdings Inc. Stock (CPHI) Latest News
China Pharma (NYSE:CPHI) Coverage Initiated by Analysts at StockNews.com - Defense World
CPHI’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
LEO Pharma Submits New Drug Application for Enstilar® for Adults with Plaque Psoriasis in China - Yahoo Finance
StockNews.com Begins Coverage on China Pharma (NYSE:CPHI) - Defense World
Yum China Holdings, Inc. (YUMC): Analysts Are Bullish On This Undervalued Cyclical Stock Now - Yahoo Finance
Investing in China Pharma Holdings Inc. (CPHI) might be an excellent idea, but the stock is currently overvalued/undervalued – US Post News - US Post News
China Pharma Holdings Inc.: Weathering Stock Market Storms with 4.04M Market Cap - The InvestChronicle
China Pharma (NYSE:CPHI) Coverage Initiated at StockNews.com - Defense World
Plasma Fractionation Market Size to Expand Lucratively by 2031 - WhaTech
China Pharma (NYSE:CPHI) Earns Hold Rating from Analysts at StockNews.com - Defense World
China Medical System Holdings First Half 2024 Earnings: EPS: CN¥0.37 (vs CN¥0.78 in 1H 2023) - Simply Wall St
Jacobio Pharma grants Allist rights to two assets in China - Yahoo Finance
Corbus Pharmaceuticals Holdings, Inc. (CRBP): One of Oppenheimer's Top Stock Picks For the Next 12 Months - MSN
HSI Down 182 pts; HSTI Down 55 pts; MEITUAN Down over 3%; HANSOH PHARMA, CKI HOLDINGS, CLP HOLDINGS, CHINA TAIPING, ASCENTAGE Hit New Highs - AASTOCKS.com
HSI Closes Midday at 17,700, Down 173 pts; HSTI Closes Midday at 3,437, Down 63 pts; NONGFU SPRING Down over 11%; HANSOH PHARMA, CKI HOLDINGS, CLP HOLDINGS, CKH HOLDINGS, CHINA TAIPING Hit New Highs - AASTOCKS.com
Corbus Pharmaceuticals Holdings, Inc. (CRBP): One of Oppenheimer’s Top Stock Picks For the Next 12 Months - Insider Monkey
Corbus Pharmaceuticals Holdings, Inc. (CRBP): One of Oppenheimer’s Top Stock Picks For the Next 12 Months - Yahoo Finance
UCB to divest China neurology and allergy business for $680m - Yahoo Finance
China Nt Pharma Group Company Limited Reports Earnings Results for the Half Year Ended June 30, 2020 - Marketscreener.com
Belgium's UCB to sell China neurology, allergy business for $680 mln - Reuters
Mayne Pharma Group Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
5 Biggest Pharmaceutical ETFs in 2024 - Investing News Network
Vanguard Group Inc. Increases Stake in iShares MSCI China ETF (NASDAQ:MCHI) - Defense World
TopBrand 2024 Top 500 Global Brands List released, with Apple as defending champion - The Manila Times
China Pharma Holdings, Inc. expects to launch its Dry Eye Disease Therapeutic Device in the first quarter of 2025 - The Manila Times
China Pharma set to launch dry eye device in Q1 2025 - Investing.com
China Pharma Holdings to launch dry eye disease therapeutic device in Q1, 2025 - BSA bureau
China Pharma Holdings, Inc. expects to launch its Dry Eye Disease Therapeutic Device in the first quarter of - Digital More
China Pharma set to launch dry eye device in Q1 2025 - Investing.com India
China Pharma Holdings, Inc. expects to launch its Dry Eye Disease Therapeutic Device in the first quarter of 2025 - Citizentribune
China Pharma Holdings, Inc. expects to launch its Dry Eye Disease Therapeutic Device in the first quarter of 2025 - StockTitan
China Pharma (NYSE:CPHI) Research Coverage Started at StockNews.com - Defense World
Insider Buying: CTO Leila Zhang Acquires Shares of Yum China Holdings Inc (YUMC) - Yahoo Finance
Decoding Yum China Holdings Inc (YUMC): A Strategic SWOT Insight - Yahoo Finance
Plasma Fractionation Market Transforming Plasma into Life-Saving Therapies: The Role of Plasma Fractionatio... - WhaTech
Tidal Investments LLC Buys New Holdings in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
Price T Rowe Associates Inc. MD Buys Shares of 267,143 UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
Yum China Holdings, Inc. (YUMC) Q2 2024 Earnings Call Transcript - Seeking Alpha
CPHI stock touches 52-week low at $0.23 amid market challenges - Investing.com Nigeria
CPHI stock touches 52-week low at $0.23 amid market challenges - Investing.com Canada
CPHI stock touches 52-week low at $0.23 amid market challenges - Investing.com
Plasma Fractionation Industry: Exploring Market Trends, Technological Advancements, and Economic Impact of ... - WhaTech
Ameritas Investment Partners Inc. Boosts Stock Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World
Vanguard Group Inc. Has $630.46 Million Stock Holdings in Yum China Holdings, Inc. (NYSE:YUMC) - Defense World
AstraZeneca CEO: We're building '2 supply chains' to avoid impact of US-China tensions - Yahoo Finance
China Pharma (NYSE:CPHI) Receives New Coverage from Analysts at StockNews.com - Defense World
Marinus Pharmaceuticals Announces Ganaxolone Approved in China as First Treatment for Seizures Associated with CDKL5 Deficiency Disorder - Yahoo Finance
Immunoglobulins Market Size & Share to Surpass USD 27.7 Billion by 2031, Projected a CAGR of 6.2% | Report by Transparency Market Research, Inc. - finanznachrichten.de
Quantbot Technologies LP Reduces Holdings in Ascendis Pharma A/S (NASDAQ:ASND) - American Banking and Market News
Ascentage Pharma Group International (OTCMKTS:ASPHF) Short Interest Up 36.3% in June - Defense World
Ascentage Pharma Group International (OTCMKTS:ASPHF) Sees Large Growth in Short Interest - American Banking and Market News
China Pharma Holdings Inc. Stock (CPHI) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.23%
0.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):